Combination treatment may help reduce lupus severity

The disease-modifying antirheumatic drug mycophenolate mofetil may be effective in patients with systemic lupus erythematosus.

In a study published in JAMA Network Open, researchers examined whether adding mycophenolate mofetil to standard therapy may reduce the incidence of severe flare-ups and lupus nephritis. They randomly assigned 130 patients aged 18 to 65 years with new-onset lupus to receive either mycophenolate mofetil in combination with standard treatment or standard treatment alone.

After 96 weeks, the researchers found that the patients in the mycophenolate mofetil plus standard treatment group experienced a lower incidence of severe flare-ups and lupus nephritis compared with those in the standard treatment alone group. Further, the rate of adverse events was comparable between the two groups.

The findings demonstrated that early administration of mycophenolate mofetil may be effective at reducing lupus severity.

Read more: JAMA Network Open

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.